Neil Woodford Dumps Centrica PLC & Buys More GlaxoSmithKline plc, Rolls-Royce Holding PLC, Legal & General Group Plc And AA PLC

Catching my eye among Neil Woodford’s latest trades are Centrica PLC (LON:CNA), GlaxoSmithKline plc (LON:GSK), Rolls-Royce Holding PLC (LON:RR), Legal & General Group Plc (LON:LGEN) and AA PLC (LON:AA).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Markets continue to be volatile, and ace fund manager Neil Woodford continues to seek out the best opportunities. As such, there was a good deal of trading reported in the latest update from the CF Woodford Equity Income Fund.

A number of moves caught my eye. In particular, Woodford dumped Centrica (LSE: CNA), and pumped more money into GlaxoSmithKline (LSE: GSK), Rolls-Royce (LSE: RR), Legal & General (LSE: LGEN) and AA (LSE: AA).

Out of gas

Woodford’s sale of British Gas owner Centrica follows on from a disposal of SSE in July, and leaves the fund holding just one utility: mid-cap electricity generator Drax.

Woodford had been a keen buyer of Centrica earlier this year, despite the company’s “disappointing dividend cut”; indeed, he had added to the holding as recently as June. However, August saw the fund reduce its position, and the sale of the remainder of the holding in September has come with an explanation:

[We have] become more concerned about its exposure to the oil price and increasing competition and regulation in downstream energy markets, both here in the UK and in the US. We think the company will now struggle to deliver growth much above low-to-mid single digits, which combined with a reduced cash return, leads to a modest total return expectation. At the prevailing valuation, therefore, the shares can no longer justify their position in the portfolio”.

Centrica trades on a 12-month forward price-to-earnings (P/E) ratio of 12.9, with a prospective yield of 5.3%. The valuation doesn’t look altogether unappealing, and investors may take some comfort from the fact that it’s not so much that Woodford sees Centrica as an awful prospect, but more a case of seeing better value elsewhere. As the fund update puts it: [Centrica] has become the latest victim of the intense fight for capital between existing positions and new ideas”.

Four tops

GlaxoSmithKline, Rolls-Royce and Legal & General were FTSE 100 underperformers during September. Woodford and his team noted: “As is often the case over shorter time periods, fundamentals have played no part in these moves. When this happens, the logical thing to do is to buy more, which is exactly what we have done”.

Indeed, in addition to these blue-chip heavyweights, the fund “took advantage of share price weakness to add to a wide range of holdings”, including FTSE 250 firm the AA.

GlaxoSmithKline has long been a core income holding for Woodford, and it’s not hard to see why he might want to buy more at this stage. The pharma giant currently offers a prospective 12-month yield on the ordinary dividend of 6.1%, which will be bumped up to 7.6% by an expected one-off special dividend.

Legal & General is Woodford’s only FTSE 100 holding in the financial sector, and he sees it as a strong growth-and-income candidate. L&G currently trades on a forward P/E of 12.1 with a yield of 5.8%.

Rolls-Royce and the AA don’t boast the high yields of Glaxo and L&G. The aerospace group offers a prospective 3.3%, while the roadside recovery firm offers 3.6%. However, the two companies have other attractions. Rolls-Royce is going through a sticky patch, but Woodford looks past a P/E of 15.1 on depressed earnings, and sees long-term value in the stock. Meanwhile, the AA — self-tagged “Britain’s fourth emergency service” — has some utility-like qualities, and, I would note, an appealingly low P/E of 11.6.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended Centrica and GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »